IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
InventorsScott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen binding fragments that specifically bind to IL-7Rα are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7Rα using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7Rα, such as acute lymphoblastic leukemia.
Claims32
An isolated monoclonal antibody that specifically binds to an extracellular domain of IL-7Rα, comprising:
- a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 1 (4A10 VH) and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 2 (4A10 VL);
- or
- a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 3 (2B8 VH) and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 4 (2B8VL).
Dependencies are inferred from the claim text.